What is Tarsus Pharmaceuticals, Inc.'s gross unrealized gains?

Tarsus Pharmaceuticals, Inc. (TARS) reported gross unrealized gains of $91K in Q1 2026.

How has Tarsus Pharmaceuticals, Inc.'s gross unrealized gains changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s gross unrealized gains decreased by 19.5% year-over-year, from $113K to $91K.

What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s gross unrealized gains?

Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s gross unrealized gains has grown at a 178.5% compound annual growth rate (CAGR), from $18K to $389K.

Tarsus Pharmaceuticals, Inc. TARS Gross Unrealized Gains

Gross Unrealized Gains at other companies

State StreetSTT

$174M-14.7%

BKBK

$204M-17.1%

PNC Financial ServicesPNC

$456M+22.6%

Provident Financial ServicesPFS

$72K+414%

Wells Fargo & CompanyWFC

$992M+79.7%

Hope BancorpHOPE

$0-100%

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s gross unrealized gains?: Tarsus Pharmaceuticals, Inc. (TARS) reported gross unrealized gains of $91K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s gross unrealized gains changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s gross unrealized gains decreased by 19.5% year-over-year, from $113K to $91K.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s gross unrealized gains?: Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s gross unrealized gains has grown at a 178.5% compound annual growth rate (CAGR), from $18K to $389K.